GLP-1 safety and pharmacy verification
How to use GLP-1 medications safely, verify a compounding pharmacy, spot counterfeit or gray-market products, and understand what compounded GLP-1 status actually means. These pages prioritize safety over conversion.
Compounded GLP-1 medications are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing. Before starting any program, verify the dispensing pharmacy is named and state-licensed, confirm a real prescription pathway, and watch for the red flags covered below. Eligibility and treatment decisions belong to a licensed clinician.
Safety and verification guides
Is compounded GLP-1 medication safe?How to verify a compounding pharmacy503A vs 503B pharmacies explainedIs compounded GLP-1 legal in 2026?Semaglutide salt forms: the red flagVerify a compounding pharmacy: checklistHow to spot counterfeit GLP-1GLP-1 telehealth red flags
| Red flag | Why it matters |
|---|---|
| No named pharmacy | You can't verify state licensing or 503A/503B status before enrolling |
| No prescription required | Legitimate GLP-1 access always requires a clinician evaluation |
| Maintenance price under ~$200 (tirzepatide) | Below the API cost floor — signals bait-and-switch or non-legitimate sourcing |
| "FDA-approved compounded" claims | Compounded drugs are never FDA-approved; this is a false claim |
| Salt forms (semaglutide sodium/acetate) | Not the active ingredient in approved products; an FDA red flag |
Compounded GLP-1 medications occupy a narrow legal lane: after the 2025 shortage resolutions, routine copies of commercially available drugs are restricted, and legitimate compounding is limited to patient-specific clinical circumstances. A provider that ignores these boundaries, hides its pharmacy, or advertises guaranteed approval is worth avoiding regardless of price.
Reporting concerns
Report suspected counterfeit medication or adverse events to the FDA through MedWatch. If you experience a serious reaction — severe abdominal pain, repeated vomiting, difficulty breathing, facial or throat swelling — seek urgent medical care. This is educational information, not medical advice.
Sources
- FDA — human drug compounding and GLP-1 status. fda.gov/drugs/human-drug-compounding
- Pricing and program data captured from provider sites and major publishers (Forbes Health, U.S. News), July 2026. Full records: evidence ledger.
- Methodology: price-index and affordability methodology.